adjuvant SRS for lesions not amenable to complete resection. In 16 of these patients a biopsy sample was obtained and examined prior to radiosurgery, and eight underwent radiosurgery within 6 months of resection to treat residual disease. Twenty-five patients underwent SRS for recurrent tumor. Additional previous therapies included fractionated radiotherapy in 13 patients, stereotactic cyst drainage in four, and VP shunt placement in four. A summary of patient data, tumor location, and multimodal therapy before radiosurgery is presented in Table 1 . The tumor volumes ranged from 0.42 to 45.1 cm 3 (median 3.3 cm 3 ), and the radiation dose to the tumor margin ranged from 9.6 to 22.5 Gy (median dose 15 Gy).
The diagnosis of pilocytic or Grade II fibrillary astrocytoma was confirmed with the aid of stereotactic biopsy sampling in 17 patients, open biopsy sampling in five, partial resection in 13, and near-total resection in 14. Analysis of tumor control was stratified according to whether the tumor was cystic, solid and circumscribed, or multifocal (diffuse). In total, 34 patients harbored solid and circumscribed pilocytic astrocytomas (25 cases) and Grade II fibrillary astrocytomas (nine cases) ( Table 1 ). In the group of patients in whom GKS was performed as an adjuvant therapy, 17 harbored tumors that were solid and circumscribed and seven harbored cystic tumors. Of patients with GKStreated recurrent tumors, 17 harbored solid and circumscribed tumors, four cystic tumors, and four multifocal tumors. All patients in this study presented for radiosurgery after evaluation of an initial biopsy sample or attempted resection. Gamma knife surgery was performed as an adjunct to stereotactic biopsy, stereotactic cyst aspiration, open biopsy sampling, or resection, or as a treatment for recurrent tumors after resection. In many patients, radiosurgery was conducted as an alternative to larger-field fractionated radiotherapy.
Radiosurgical treatment began with rigid fixation of an imaging-compatible Leksell stereotactic frame (model G; Elekta Instruments, Atlanta, GA) to the patient's head. Regional anesthetic scalp infiltration (5% marcaine and 1% xylocaine buffered with sodium bicarbonate) and mild sedation were used. General anesthesia was induced in children younger than 12 years of age. Stereotactic CT scanning was used for target localization and planning prior to 1993, after which we used MR imaging because of its better image resolution, superior tissue contrast, and virtually artifact-free visualization. After 1993, CT scanning was performed only if MR imaging was contraindicated because of metal implants in the body. High-resolution Gd-enhanced T 1 -weighted sagittal scout MR images were obtained first to localize the area of interest. To define the radiosurgical target volume, multiplanar volume-acquisition contrast-enhanced MR images (divided into 28-60 axial slices of 1-mm thickness) were acquired. All of the pilocytic astrocytomas enhanced after administration of contrast on CT scanning or MR imaging. Patients with Grade II fibrillary astrocytomas additionally underwent long-repetition time MR imaging to delineate better any edema from nonenhancing tumor tissue. These images were transported via fiberoptic ethernet to a highspeed computer workstation for gamma knife treatment planning. The planning was performed on axial images supplemented by coronal and sagittal reformatted images. A conformal plan was achieved using multiple isocenters of different diameters. The treatment volume for pilocytic astrocytomas consisted of the enhancing component of the tumor and cyst wall if present. For Grade II fibrillary astrocytomas, the treatment volume consisted of the nonenhancing tumor tissue. After finalizing the plan, a maximum margin dose was determined. The treatment isodose, maximum dose, and margin dose were jointly decided by a neurosurgeon, radiation oncologist, and medical physicist. The dose was selected based on tumor volume, location, and estimated tolerance of nearby critical structures, especially if prior fractionated radiotherapy had been administered. Radiosurgery was performed with a 201-source, 60 Co Leksell gamma knife (Model U or Model B; C. G. Hadjipanayis, et al. Elekta Instruments) by positioning the target serially at x, y, and z coordinates of each isocenter. All patients received a 10-to 40-mg dose of methylprednisolone at the conclusion of the procedure. The stereotactic frame was removed immediately afterwards, and patients were discharged within the next 6 to 18 hours. All patients underwent serial follow-up imaging studies (usually MR imaging), which were requested at 3-, 6-, 12-, and 24-month intervals if no tumor growth was noted. In case of neurological deterioration, interval images were obtained. If there was no appreciable change in tumor size, subsequent MR images were requested at 1-year intervals. Patients who lived a long distance from Pittsburgh were evaluated by their referring physician who forwarded the imaging and clinical data to the Center for ImageGuided Neurosurgery at the University of Pittsburgh. Patients or their families were also contacted by telephone to optimize the follow-up data.
RESULTS

Clinical Outcomes
Forty-five (92%) of 49 patients are alive at a median follow-up length of 32 months after radiosurgery (range 3-159 months) and 63 months after diagnosis (range 2-186 months). Procedure-related permanent morbidity or mortality did not occur in this series. In one patient the Karnofsky Performance Scale score was 30; otherwise, in all surviving patients in this study scores ranged from 80 to 100 as of last follow-up examination. Three patients died of local tumor progression 23, 72, and 115 months after diagnosis, respectively, and 7, 71, and 29 months after GKS. One patient died of respiratory failure caused by pneumonia unrelated to brain tumor.
Adverse Effects of Radiation
Two patients experienced a temporary worsening of their neurological conditions after radiosurgery. Magnetic resonance imaging revealed increased contrast enhancement of the tumor associated with T 2 -weighted sequence changes of the surrounding brain. One patient suffered a deterioration in speech 6 months after radiosurgery and 12 months after fractionated radiation therapy. Staff at an outside institution believed tumor recurrence had developed, and the patient received steroid therapy and was started on a new chemotherapeutic regimen (ifosfamide, carboplatin, and etoposide). We believe the imaging-related changes associated with the patient's clinical deterioration were due to radiation effect, not tumor recurrence. On followup imaging 24 months after radiosurgery, there was decreased enhancement and T 2 -weighted change associated with the tumor. The patient exhibited no expressive aphasia at last clinical follow up. The other patient experienced slight worsening of his hemiparesis 7 months after radiosurgery, which eventually improved. By 28 months after radiosurgery, greater than 50% reduction in size of his tumor had been achieved.
Imaging Results
Follow-up imaging studies demonstrated tumor control in 33 (67%) of 49 patients. Complete resolution was identified in 11 patients and reduction in tumor volume in 12 patients. In ten patients the appearance of the tumor remained unchanged after radiosurgery. In 16 patients (33%) delayed tumor growth was observed; in eight of these patients there was an increase in cyst size only (Tables 2 and 3) .
Tumor control was achieved in 17 (71%) of 24 patients in whom radiosurgery was performed as an adjuvant and in 16 (64%) of 25 patients with recurrent tumors. In the adjuvant setting, complete resolution of the tumor was confirmed in six patients, reduction in tumor size in six patients, and no change in tumor size in five patients. In seven other patients (29%) local tumor progression was identified on follow-up images. In four patients there was an increase in cyst size only. One patient died of local tumor progression 71 months after radiosurgery. Among patients with GKS-treated recurrent tumors, complete resolution was documented in five patients, reduction in tumor size in six, and no change in tumor size in five. In nine patients (36%) local tumor progression was noted on follow-up images, in four of whom there was an increase in cyst size only. Two patients died of local tumor progression 7 and 29 months, respectively, after radiosurgery.
Tumor control was achieved in 29 (85%) of 34 patients with solid, circumscribed tumors and was verified with the aid of images obtained after radiosurgery (Fig. 1) . In nine patients complete resolution of tumor was demonstrated on follow-up images; in 11 patients a reduction in tumor size was observed; in nine patients there was no change in tumor size; and in five (15%) local tumor progression was identified. Local tumor progression was exhibited in three of four patients who harbored multifocal tumors according to follow-up data; two of these patients died. In eight of 11 patients with cystic tumors there was an increase only in cyst size after radiosurgery.
Low-Grade Astrocytomas Located in the Brainstem
Progressive lesions were located in the brainstem in 22 patients. In 15 (68%) of these patients the lesions were solid, circumscribed tumors; in three (14%) they were cystic; and in four patients (18%) they were multifocal. Tumor control was achieved in 13 (59%) of 22 patients after radiosurgery. In four patients there was complete resolution, in six there was a decrease in tumor size, and in three the tumor size was stable after radiosurgery. Follow-up imaging demonstrated tumor progression in nine patients (41%). Two patients underwent additional cytoreductive surgery. Three patients died of local tumor progression.
Twelve patients with tumors located in the brainstem (16) underwent adjuvant radiosurgery. In eight (67%) tumor control was achieved after radiosurgery, and in four (33%) there was evidence of tumor progression on follow-up images. In three of the latter there was an increase in cyst size only. Ten patients underwent GKS for recurrent tumors located in the brainstem. In five patients (50%) tumor control was achieved, and in five others (50%) tumor progression was evident on follow-up images.
Biopsy Procedure Followed by Radiosurgery
In this series, 16 patients underwent biopsy sampling, performed by open surgery in three patients or stereotactically in 13, before they underwent radiosurgery (Fig. 2) . The location of these tumors included the brainstem in eight patients, the parietal lobe in three, the thalamus in two, and the frontal lobe (periventricular), temporal lobe (medial), and third ventricle in one patient each. These patients had not undergone previous tumor resection. Two patients with Grade II fibrillary astrocytomas underwent fractionated radiotherapy prior to GKS. One patient underwent placement of a VP shunt, and one patient underwent two stereotactic cyst aspirations prior to GKS. Two patients underwent additional therapy after radiosurgery: fractionated radiotherapy 9 months following radiosurgery at another institution in one patient with worsening hemiparesis and stereotactic cyst drainage in the second patient due to cyst progression.
In 12 (75%) of 16 patients tumor control was achieved by the last follow-up examination. In five patients complete resolution of tumor was confirmed on follow-up images. Follow-up imaging demonstrated a reduction in tumor size in four patients and stable tumor size in four patients. Tumor progression was identified in four patients (25%). One patient died of local tumor progression.
Treatment After Radiosurgery
Among the 16 patients in whom there was delayed tumor growth, five required additional cytoreductive surgery. In one patient with a Grade II fibrillary astrocytoma there was solid tumor progression, which on microscopic examination was shown to be anaplastic astrocytoma. In eight patients there was only an increase in tumor cyst size. Five patients underwent stereotactic cyst drainage. One patient underwent stereotactic intracavitary 32 P irradiation. Two patients with cyst progression have not undergone any additional procedure after radiosurgery but may require future stereotactic cyst aspiration. One patient underwent repeated GKS. Other treatments following radiosurgery included stereotactic intracavitary irradiation in four, chemotherapy in two, and fractionated radiotherapy and VP shunt placement in one patient each.
DISCUSSION
Treatment Modalities
The potential role of radiosurgery for patients with selected low-grade astrocytomas has yet to be defined. Whenever possible, symptomatic or progressive pilocytic astrocytomas should be resected completely. 10, 19, 21, 28, 30 Even after partial removal of the tumor, patients with pilocytic astrocytomas can undergo observation involving periodic imaging examinations before additional surgery or other treatment modalities need to be performed. 3, 4 For those patients in whom total or subtotal resection cannot be safely performed, radiotherapy and/or chemotherapy have often been recommended. 9, 10, 18, 20, 22, [44] [45] [46] Although better disease-free survival has been reported in radiotherapy or chemotherapy series, significant adverse effects on patients have been associated with these two treatment modalities. Adverse effects of cerebral irradiation include memory impairment, learning disabilities, progressive deterioration in intelligence, endocrinopathies, and malignant transformation of tumors. 5, 8, 11, 12, 14, 16, 49 Chemotherapy can cause significant systemic toxicity. 44 Radiosurgery has been considered as a primary alternative to radiotherapy.
Management of Grade II fibrillary astrocytomas is controversial, and practice parameters are ill defined. 24, 31 Cytoreductive surgery is indicated to relieve the symptoms of raised intracranial pressure secondary to tumor mass effect. Complete resection of these tumors is rarely possible because by nature they are infiltrative. Some authors have reported the extent of excision as a prognostic variable, but this has not been confirmed in other studies in which multivariate analysis has been conducted. 6, 7, 27, 29, 31, 36, 40, 47 Nevertheless, tissue diagnosis of these tumors needs to be performed either by stereotactic biopsy sampling or resection. Many of these tumors gradually transform from a slower growth rate with a lower mitotic index to an anaplastic form with a higher mitotic index. 1, 2, 15 In previously published studies investigators have defined the benefit of fractionated external-beam radiotherapy as an adjuvant in the management of patients who C. G. Hadjipanayis, et al. underwent either biopsy sampling or cytoreductive surgery for Grade II fibrillary astrocytoma. 6, 35, 37, 43, 48, 50, 52 In patients with long-term survival after fractionated brain irradiation there is the risk developing radiation-induced late-onset leukoencephalopathy and cognitive impairment. 42, 53, 54 Role of Radiosurgery For brain tumors, the efficacy of conventional fractionated radiotherapy is dependent on the differential biological sensitivity of normal and tumor cells to radiation. Growth kinetics of pilocytic and Grade II astrocytomas make the radiosensitivity of normal cells and neoplasm very similar. Because of its capability to deliver a high radiation dose to tumor with a sharp falloff to normal surrounding tissue, radiosurgery is not limited by the biological differential sensitivity of tumor and normal cells. The goal of radiosurgery is to arrest the cell-division capability of target cells irrespective of the individual cell's mitotic activity and radiosensitivity. Radiosurgery also allows for delayed intratumoral vascular obliteration. In the treatment of cases involving the developing nervous system, the opportunity to use focused radiation to the lesion represents an attractive treatment alternative that may reduce the potential long-term risks of cognitive or endocrinological dysfunction associated with fractionated radiation therapy. 34 Additionally SRS also eliminates the potential systemic toxicity observed with chemotherapy.
The majority of radiosurgery studies have focused on the treatment of malignant gliomas. We could only find one published series by Kida, et al., 32 on radiosurgery for low-grade astrocytomas that included 39 patients with Grade II astrocytomas and 12 patients with pilocytic astrocytomas. These authors treated patients using a median margin dose of 15.7 Gy for Grade II astrocytomas and 12.5 Gy for pilocytic astrocytomas. Tumor response (regression) and control rates of 46.2 and 87.2%, respectively, for Grade II astrocytomas, and 50 and 91.7%, respectively, for pilocytic astrocytomas were achieved. Radiation-induced edema was noted in 35% of the patients and close to 50% of these were symptomatic requiring steroid administration. These authors also noted cyst formation and temporary tumor swelling (7.7%) after radiosurgery.
Patients with progressive, pilocytic, or Grade II fibrillary astrocytomas, located in critical or deep areas of the brain, are ideal candidates for radiosurgery. In our series of 49 patients, tumor control was achieved in 33 (67%). For patients with solid, circumscribed tumors the disease control rate was 85%. Radiosurgery was performed as part of multimodal therapy in the majority of patients in the series. No permanent complications occurred following radiosurgery, and all 45 patients who remain alive are without cognitive or endocrinological deficits.
We have shown in the past that SRS for intraparenchymal brainstem tumors can be performed safely. 33 In our series 22 patients harbored progressive lesions located in the brainstem. In 13 patients (59%) tumor control was achieved after radiosurgery. No patient with a brainstem lesion suffered any procedure-related morbidity or mortality after SRS.
Biopsy Procedure Followed by SRS
A biopsy procedure followed by radiosurgery of histologically proven pilocytic or Grade II fibrillary astrocytoma is a potential treatment alternative in patients with solid, circumscribed tumors who do not undergo resection. In this series, 16 patients underwent biopsy sampling and subsequent radiosurgery. Tumor control was achieved in 75%. The majority (69%) of these lesions were solid, circumscribed tumors.
The Risks of Radiosurgery
The two patients believed to have experienced adverse radiation-induced effects after radiosurgery both exhibited improvement in clinical condition and imaging-documented tumor characteristics 24 and 28 months, respectively, after GKS.
CONCLUSIONS
The use of SRS as part of multimodal therapy for pro-
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